Insider Selling: Twist Bioscience (NASDAQ:TWST) Insider Sells $57,590.52 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 348 shares of the firm’s stock in a transaction on Monday, September 21st. The shares were sold at an average price of $165.49, for a total value of $57,590.52. Following the completion of the sale, the insider owned 73,303 shares in the company, valued at approximately $12,130,913.47. This represents a 0.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dennis Cho also recently made the following trade(s):

• On Tuesday, September 8th, Dennis Cho sold 412 shares of Twist Bioscience stock. The stock was sold at an average price of $122.62, for a total transaction of $50,519.44.

Twist Bioscience Stock Performance

NASDAQ TWST traded down $6.10 on Wednesday, reaching $158.50. The stock had a trading volume of 2,133,311 shares, compared to its average volume of 1,563,605. The stock has a market cap of $9.94 billion, a P/E ratio of -71.40 and a beta of 2.22. The business’s 50-day moving average price is $121.94 and its 200 day moving average price is $84.72. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $170.66.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The company had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The firm’s revenue was up 23.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.33 earnings per share. As a group, equities analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently modified their holdings of the company. Engineers Gate Manager LP acquired a new stake in shares of Twist Bioscience in the 2nd quarter worth approximately $3,333,000. Integrated Wealth Concepts LLC bought a new stake in shares of Twist Bioscience in the 2nd quarter worth approximately $99,000. Allworth Financial LP lifted its holdings in shares of Twist Bioscience by 54.9% during the second quarter. Allworth Financial LP now owns 601 shares of the company’s stock valued at $62,000 after purchasing an additional 213 shares during the last quarter. Nykredit A S acquired a new position in shares of Twist Bioscience in the second quarter worth about $283,000. Finally, Allianz Asset Management GmbH acquired a new stake in Twist Bioscience during the 2nd quarter worth about $1,327,000.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. UBS Group started coverage on Twist Bioscience in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $144.00 price target on the stock. BWS Financial reissued a “sell” rating and issued a $45.00 price objective on shares of Twist Bioscience in a research report on Friday, September 18th. Leerink Partners lifted their price target on Twist Bioscience from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Thursday, September 17th. Robert W. Baird lifted their target price on Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Finally, Guggenheim restated a “buy” rating on shares of Twist Bioscience in a report on Monday, August 24th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Twist Bioscience has an average rating of “Moderate Buy” and a consensus price target of $103.00.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.